Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of prostate adenocarcinoma.~* Metastatic prostate cancer progressive on imaging studies and/or rising PSA despite adequate medical or surgical castration therapy.~* Progressed following discontinuation of anti-androgen therapy, if received.~* Serum testosterone \< 50 ng/ml~Exclusion Criteria:~* Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of treatment.~* Use of PC-SPES within 4 weeks of treatment.~* Use of red blood cell or platelet transfusions within 4 weeks of treatment.~* Use of hematopoietic growth factors within 4 weeks of treatment.~* Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.~* Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton.~* Prior radiation therapy encompassing \>25% of skeleton.~* Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).~* Active angina pectoris or NY Heart Association Class III-IV.~* History of deep vein thrombophlebitis and/or pulmonary embolus within 3 months of study entry.~* Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.~* Prior monoclonal antibody therapy with the exception of ProstaScint®~* Prior investigational therapy (medications or devices) within 6 weeks of treatment.~* Known history of HIV

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).